Laboratorios Farmaceuticos ROVI

Research Laboratorios Farmaceuticos ROVI (ROVI) on Bullrun: valuation model: 5.7% undervalued, market cap EUR 3.04B, P/E 23.0, dividend yield 1.6%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerROVI
• ExchangeMC
• CountrySpain
• SectorHealthcare
• IndustryDrug Manufacturers - Specialty & Generic
• CurrencyEUR
• Valuation signal5.7% undervalued
• Market capEUR 3.04B
• P/E23.0
• Dividend yield1.6%
• Financial periodFY2024
• RevenueEUR 763.75M
• Revenue growth-7.9%
• Net incomeEUR 136.88M
• Free cash flowEUR 79.16M

Valuation Snapshot

Bullrun's latest valuation model marks Laboratorios Farmaceuticos ROVI as 5.7% undervalued; latest market cap is EUR 3.04B; P/E is 23.0; dividend yield is 1.6%.

About Laboratorios Farmaceuticos ROVI

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa.

Frequently asked questions

Is Laboratorios Farmaceuticos ROVI overvalued or undervalued?

Bullrun's valuation model currently marks Laboratorios Farmaceuticos ROVI as 5.7% undervalued.

What is Laboratorios Farmaceuticos ROVI's market cap?

Laboratorios Farmaceuticos ROVI's market capitalization is EUR 3.04B.

What is Laboratorios Farmaceuticos ROVI's P/E ratio?

Laboratorios Farmaceuticos ROVI's price-to-earnings (P/E) ratio is 23.0.

Does Laboratorios Farmaceuticos ROVI pay a dividend?

Laboratorios Farmaceuticos ROVI has a dividend yield of 1.6%.

What does Laboratorios Farmaceuticos ROVI do?

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally.